Competitor Analysis: Alzheimer’s Disease Antibodies

The Competitive Intelligence Report Alzheimer's Disease Antibodies as of July 2008 provides a competitor analysis in the development pipeline of novel antibodies for passive immunotherapy of Alzheimer’s disease including those targeting amyloid-beta (beta-amyloid). Among the companies active in the field of new antibodies for passive immunotherapy of Alzheimer’s disease Wyeth, Elan, Pfizer, Roche and many others. The report includes a compilation of current active projects in research and development of novelantibodies for passive immunotherapy of Alzheimer’s disease. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.

Additional Information

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.